Koss-Olinger Consulting’s Twist Bioscience TWST Stock Holding History

Koss-Olinger Consulting’s Portfolio TWST Stock Details TWST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-41,300	Closed	-$845K	–	307
2023 Q2	$845K	Hold	41,300	–	–	0.1%	102
2023 Q1	$623K	Buy	+41,300	New	+$912K	0.08%	118
2021 Q3	–	Sell	-21,500	Closed	-$2.87M	–	274
2021 Q2	$2.87M	Hold	21,500	–	–	0.43%	24
2021 Q1	$2.66M	Buy	+21,500	New	+$3.26M	0.45%	27

Other funds holding TWST

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Koss-Olinger Consulting's TWST Position: Q3 2023 in Review

Koss-Olinger Consulting sold out of Twist Bioscience (TWST) in Q3 2023, closing a stake of 41,300 shares — an estimated $845K sold.

Koss-Olinger Consulting first reported a position in TWST in Q1 2021 and held it in 4 quarters. The position peaked at $2.87M in Q2 2021. 194 funds tracked by Wall St. Rank hold TWST as of Q3 2023.

Koss-Olinger Consulting reported no remaining Twist Bioscience position as of Q3 2023 after selling out during the quarter.
Koss-Olinger Consulting sold 41,300 Twist Bioscience shares in Q3 2023, an estimated $845K.
Koss-Olinger Consulting first reported a position in Twist Bioscience in Q1 2021 and held it in 4 quarters.
Koss-Olinger Consulting's Twist Bioscience position peaked at $2.87M in Q2 2021.
194 funds tracked by Wall St. Rank held Twist Bioscience as of Q3 2023.

Based on Koss-Olinger Consulting's 13F filing for Q3 2023, filed 11 Oct 2023.